Allogene Therapeutics, Inc. (ALLO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22K | -44K | 22K | 22K |
| Revenue Growth % | - | - | - | - | -100% | 100% | -100% | -100% | -26.67% | -193.62% | -55.1% | -74.42% |
| Cost of Goods Sold | 2.87M | 3.06M | 31.16M | 0 | 3.1M | 3.23M | 0 | 0 | 3.56M | 0 | 3.57M | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 16159.09% | - | 16236.36% | - |
| Gross Profit | -2.87M | -3.06M | -31.16M | 0 | -3.1M | -3.23M | 0 | 0 | -3.53M | -44K | -3.55M | 22K |
| Gross Margin % | - | - | - | - | - | - | - | - | -16059.09% | 100% | -16136.36% | 100% |
| Gross Profit Growth % | 7.42% | 5.44% | - | - | 12.28% | -7247.73% | 100% | -100% | -11876.67% | -193.62% | -7344.9% | -74.42% |
| Operating Expenses | 43.22M | 39.35M | 13.74M | 56.82M | 62.09M | 57.26M | 71.77M | 71.43M | 65.97M | 85.13M | 59.45M | 80.56M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 299868.18% | -193477.27% | 270209.09% | 366190.91% |
| Selling, General & Admin | 14.09M | 13.77M | 13.74M | 14.28M | 14.99M | 15.52M | 16.33M | 16.09M | 17.27M | 17.22M | 17.04M | 18.52M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 78486.36% | -39145.45% | 77459.09% | 84200% |
| Research & Development | 29.13M | 28.63M | 31.16M | 40.16M | 50.2M | 44.97M | 44.71M | 50.35M | 52.26M | 54.66M | 45.98M | 62.04M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 237540.91% | -124229.55% | 208986.36% | 281990.91% |
| Other Operating Expenses | 0 | -1000K | -1000K | 1000K | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K | -1000K | 0 |
| Operating Income | -46.09M | -42.4M | -44.9M | -56.82M | -65.19M | -60.49M | -71.77M | -71.43M | -69.5M | -85.17M | -63M | -80.54M |
| Operating Margin % | - | - | - | - | - | - | - | - | -315927.27% | 193577.27% | -286345.45% | -366090.91% |
| Operating Income Growth % | 29.3% | 29.9% | 37.44% | 20.46% | 6.21% | 28.98% | -13.93% | 11.31% | 29.86% | 11.62% | 23.63% | -5.15% |
| EBITDA | -43.22M | -39.35M | -41.8M | -53.71M | -62.09M | -57.26M | -68.57M | -67.79M | -65.95M | -81.7M | -59.42M | -76.9M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -299768.18% | 185675% | -270109.09% | -349531.82% |
| EBITDA Growth % | 30.39% | 31.28% | 39.03% | 20.76% | 5.85% | 29.92% | -15.39% | 11.85% | 31% | 12.44% | 24.42% | -5.46% |
| D&A (Non-Cash Add-back) | 2.87M | 3.06M | 3.1M | 3.11M | 3.1M | 3.23M | 3.21M | 3.64M | 3.56M | 3.48M | 3.57M | 3.64M |
| EBIT | -46.09M | -42.4M | -41.06M | -50.67M | -59.58M | -59.41M | -66.19M | -66.36M | -65M | -71.93M | -62.29M | -80.54M |
| Net Interest Income | 3.27M | 3.35M | -344K | 5.92M | 5.37M | 2.95M | 6.61M | 4.99M | 5.43M | 6.26M | 6.21M | 3.78M |
| Interest Income | 3.57M | 3.66M | 0 | 6.19M | 5.52M | 3.03M | 6.71M | 4.99M | 5.43M | 6.26M | 6.21M | 3.78M |
| Interest Expense | 300K | 313K | 344K | 268K | 150K | 81K | 100K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.48M | 3.59M | 3.5M | 5.88M | 5.46M | 994K | 5.48M | 5.07M | 4.5M | -4.08M | 709K | 1.31M |
| Pretax Income | -42.61M | -38.81M | -41.4M | -50.94M | -59.73M | -59.5M | -66.29M | -66.36M | -65M | -89.26M | -62.29M | -79.23M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -295454.55% | 202856.82% | -283122.73% | -360145.45% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 443K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.74% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.61M | -38.81M | -41.4M | -50.94M | -59.73M | -59.94M | -66.29M | -66.36M | -65M | -89.26M | -62.29M | -79.23M |
| Net Margin % | - | - | - | - | - | - | - | - | -295454.55% | 202856.82% | -283122.73% | -360145.45% |
| Net Income Growth % | 28.67% | 35.25% | 37.55% | 23.23% | 8.1% | 32.85% | -6.43% | 16.25% | 34.98% | 5.89% | 25.09% | -5.94% |
| Net Income (Continuing) | -42.61M | -38.81M | -41.4M | -50.94M | -59.73M | -59.94M | -66.29M | -66.36M | -65M | -89.26M | -62.29M | -79.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.51 | -0.37 | -0.54 |
| EPS Growth % | 35.71% | 39.29% | 40.63% | 34.29% | 26.32% | 45.1% | 13.51% | 35.19% | 44.12% | 22.73% | 36.21% | -3.85% |
| EPS (Basic) | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.51 | -0.37 | -0.54 |
| Diluted Shares Outstanding | 240.29M | 220.62M | 222.04M | 218.93M | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M | 168.34M | 167.65M | 146.8M |
| Basic Shares Outstanding | 240.29M | 220.62M | 222.04M | 218.93M | 215.36M | 210.57M | 209.19M | 190.03M | 169.13M | 168.34M | 167.65M | 146.8M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |